Oncology Institute (DFPH) Net Income towards Common Stockholders (2020 - 2026)

Oncology Institute (DFPH) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$2.1 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 86.97% year-over-year to -$2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.3 million (up 31.29% YoY) and the FY2025 annual result came in at -$50.3 million, up 5.09% from the prior year.
• Net Income towards Common Stockholders rose to -$2.1 million in Q1 2026, from -$6.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $19.3 million in Q1 2022 to a low of -$30.0 million in Q1 2023.
• A 5-year average of -$11.3 million and a median of -$13.2 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 238.35% in 2022, down 673.67% in 2022.
• Tracing DFPH's Net Income towards Common Stockholders over 5 years: stood at -$11.0 million in 2022, then plunged by 70.38% to -$18.8 million in 2023, then jumped by 42.27% to -$10.8 million in 2024, then soared by 40.63% to -$6.4 million in 2025, then surged by 67.42% to -$2.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.1 million (Q1 2026), -$6.4 million (Q4 2025), and -$13.8 million (Q3 2025), per Business Quant data.